knowledge -WSS

knowledge

author：knowledge 2025-09-14 14:48:59 - browse：27684

Adobe

The Food and Drug Administration is expected to approve Merck’s drug to treat a rare lung disorder called pulmonary arterial hypertension on Tuesday, making available a novel treatment for a deadly condition that’s long been challenging to treat.

In a large trial published last year, the drug, called sotatercept, exceeded expectations in significantly increasing the distance that patients could walk and cutting the risk that their condition would worsen, that they would die, and that they would need new treatments.

Pulmonary arterial hypertension, or PAH, is estimated to occur in 15 to 50 per million people, mostly in women. It’s characterized by a proliferation of cells in the blood vessels that connect the right side of heart to the lungs, making it harder for blood to pass through and leading the heart to have to work harder to pump blood into the lungs. The disease, which causes difficulty breathing, fatigue and dizziness, has a high mortality rate, with one study finding that one-fifth of patients died at around three years after diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Gilead might be held responsible for not developing a drug

focus

WSS

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

'Revelatory' study finds a smoking impact that remains after quitting

The Readout: Gilead, Bernie Sanders, and other pharma news

eGenesis tests gene

Robert F. Kennedy is pitching centrism on health, even on abortion

Gilead might be held responsible for not developing a drug

hotspot

knowledge

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

The dental labor crisis is a moment of opportunity

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Dobbs anniversary: the lost opportunity of abortion as health care

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Sports medicine is finally prioritizing gender equality

The dental labor crisis is a moment of opportunity

As demand for Covid shots wanes, Moderna seeks its next success

How digital tools helped lower hypertension in marginalized patients

Wikipedia

The surgeon had a dilemma only a Nazi medical text could resolve

'Revelatory' study finds a smoking impact that remains after quitting

A disappointing year of Humira biosimilars

Why doctors need education on FDA device approval process

Medicare Advantage proposed rates disappoint insurers

Key House Republican on health care plans exit from Congress

entertainment

knowledge

focus

focus